Pain Relief Medication Market Research Report - Global Forecast till 2027

Global Pain Relief Medication Market Research Report: By Drug Class (Nonsteroidal Anti-Inflammatory Drugs, Opioids, Others), By Indication (Cancer Pain, Neuropathic Pain, Musculoskeletal Pain, Others) and By Distribution Channel (Hospital and Retail Pharmacies, Online Pharmacies) – Forecast to 2027

ID: MRFR/HC/6959-HCR | February, 2021 | Region : Global

Market Forecast


Pain Relief Medication Market held a value of USD 55,275 Million in 2018, at a CAGR of 4.73% during the assessment period of 2019 to 2025.


Market Synopsis


There has been a high level of product approvals by prominent players in the market. There has been an increasing prevalence of chronic and life-threatening diseases, which increases the pool of patients suffering from pain.


Market Influencer


The increasing initiatives by public and private companies boost market growth. The rising number of product launches by major players in the market are likely to act as a substantial contributing factor for the increase in the near future.


Market Drivers




  • Increasing product approvals. In November 2018, Pfizer Inc. was granted pediatric exclusivity for its product Lyrica (pregabalin), which has been approved in the US for diabetic nerve pain, fibromyalgia, spinal cord injury nerve pain, and pain after shingles in adults.




  • Increasing research initiatives




  • Rising need for treatment of chronic pain. An approximate of 20% to 24% of patients suffering from diabetic neuropathy go through pain in the US, leading to the growth of this market in the region.




  • High prevalence of life-threatening diseases




  • Growing awareness regarding the treatment of chronic diseases




  • Fast-track approval of drugs




  • Increase in the use of combination therapy for the management of pain




Market Restraints



  • Side-effects associated with the drugs

  • Increasing product recalls

  • Expiry of patents of blockbuster drugs in the pain management area


Segmentation


By Drug Class



  • Nonsteroidal Anti-Inflammatory Drugs: These classes of drugs help in reducing inflammation. The largest segment is widely used with a high efficacy rate.

  • Opioids: Fastest growing segment as they are considered one of the most effective drug classes for the treatment of chronic pain.

  • COX-2 Inhibitors: These are analgesics that were developed to inhibit only the cyclooxygenase enzyme.

  • Others: The other segment includes drugs from other classes such as anesthetics, anticonvulsants, and antimigraine drugs.


By Indication



  • Cancer Pain: This is expected to be the largest segment, owing to a large number of cancer patients. Cancer pain depends on the type of cancer, the stage of the disease, and the pain threshold of the patient.

  • Neuropathic Pain: Neuropathic pain is caused by a lesion or disease of the somatosensory nervous system. Neuropathic pain is often described as burning, tingling, electrical, stabbing or pins and needles.

  • Musculoskeletal Pain: Musculoskeletal pain affects the bones, muscles, ligaments, tendons, and nerves. Musculoskeletal pain can be localized in one area or can be widespread throughout the body.

  • Inflammatory Conditions: Inflammatory conditions include allergy, coeliac disease, asthma, autoimmune diseases, glomerulonephritis, hepatitis, and inflammatory bowel disease.

  • Others: The other segment includes facial pain and migraine.


By Distribution Channel



  • Hospital and Retail Pharmacies: Hospital and retail pharmacies are estimated to be the largest segment due to the increasing number of hospitals in-visits.



  • Online Pharmacies: Online pharmacies is expected to be the fastest-growing segment due to the increasing awareness and adoption of this type of distribution channel.


By Region




  • Americas: Americas is estimated to be the largest regional market. Countries such as the US and Canada have well-established research centers and headquarter most of the key companies. This contributes to the growth of the pain relief medication market in this region. An approximate of 20% to 24% of patients suffering from diabetic neuropathy go through pain in the US.




  • Europe: The increasing research for novel treatments and the rise in incidence rates of chronic diseases is expected to drive the growth of the pain relief medication market in the European region. An aggregate of Euro 12.3 billion (USD 13.50 billion) is spent annually in the UK for back pain treatment.




  • Asia-Pacific: Asia-Pacific is anticipated to be the fastest-growing region in the global pain relief medication market. This region is seeing a surge in the number of people afflicted with pain and the increase in the number of cancer patients. The number of new cancer cases on an annual basis account for almost 4,285,033 in China.




  • Middle East & Africa: The smallest market due to limited healthcare infrastructure and limited exposure to innovative products.




Key Players



  • AbbVie Inc. (US)

  • Astellas Pharma Inc. (Japan)

  • Allergan PLC (Ireland)

  • Bayer (Germany)

  • Purdue Pharma (US)

  • Boehringer Ingelheim International GmbH (Germany)

  • Bristol-Myers Squibb (US)

  • Eli Lilly and Company (US)

  • Mallinckrodt Pharmaceuticals (UK)

  • Biogen Idec (US)

  • GlaxoSmithKline (UK)

  • Pfizer, Inc. (US)

  • Sanofi (France)

  • Teva Pharmaceutical Industries Ltd (Israel)

Table of Contents

1. EXECUTIVE SUMMARY

1.1. Market Attractiveness Analysis

1.1.1. Global Pain Relief Medication Market, by Drug Class

1.1.2. Global Pain Relief Medication Market, by Indication

1.1.3. Global Pain Relief Medication Market, by Distribution Channel

2. MARKET INTRODUCTION

2.1. Definition

2.2. Scope of the Study

2.2.1. Research Objective

2.2.2. Assumptions

2.2.3. Limitations

3. RESEARCH METHODOLOGY

3.1. Overview

3.2. Data Mining

3.3. Secondary Research

3.4. Primary Research

3.5. Breakdown of Primary Respondents

3.6. Forecasting Techniques

3.7. Research Methodology for Market Size Estimation

3.7.1. Bottom-Up Approach

3.7.2. Top-Down Approach

3.8. Data Triangulation

3.9. Validation

4. MARKET DYNAMICS

4.1. Overview

4.2. Drivers

4.3. Restraints

4.4. Opportunities

5. MARKET FACTOR ANALYSIS

5.1. Porter’s Five Forces Analysis

5.1.1. Bargaining Power of Suppliers

5.1.2. Bargaining Power of Buyers

5.1.3. Threat of New Entrants

5.1.4. Threat of Substitutes

5.1.5. Intensity of Rivalry

5.2. Value Chain Analysis

5.2.1. R&D and Designing

5.2.2. Manufacturing

5.2.3. Distribution & Sales

5.2.4. Post Sales Services

6. GLOBAL PAIN RELIEF MEDICATION MARKET, BY DRUG CLASS

6.1. Overview

6.2. Nonsteroidal Anti-Inflammatory Drugs

Market Estimates & Forecast, by Region, 2020-2027

Market Estimates & Forecast, by Country, 2020-2027

6.3. Opioids

Market Estimates & Forecast, by Region, 2020-2027

Market Estimates & Forecast, by Country, 2020-2027

6.4. COX-2 Inhibitors

Market Estimates & Forecast, by Region, 2020-2027

Market Estimates & Forecast, by Country, 2020-2027

6.5. Others

Market Estimates & Forecast, by Region, 2020-2027

Market Estimates & Forecast, by Country, 2020-2027

7. GLOBAL PAIN RELIEF MEDICATION MARKET, BY INDICATION

7.1. Overview

7.2. Cancer Pain

Market Estimates & Forecast, by Region, 2020-2027

Market Estimates & Forecast, by Country, 2020-2027

7.3. Neuropathic Pain

Market Estimates & Forecast, by Region, 2020-2027

Market Estimates & Forecast, by Country, 2020-2027

7.4. Musculoskeletal Pain

Market Estimates & Forecast, by Region, 2020-2027

Market Estimates & Forecast, by Country, 2020-2027

7.5. Inflammatory Conditions

Market Estimates & Forecast, by Region, 2020-2027

Market Estimates & Forecast, by Country, 2020-2027

7.6. Others

Market Estimates & Forecast, by Region, 2020-2027

Market Estimates & Forecast, by Country, 2020-2027

8. GLOBAL PAIN RELIEF MEDICATION MARKET, BY DISTRIBUTION CHANNEL

8.1. Overview

8.2. Hospital and Retail Pharmacies

Market Estimates & Forecast, by Region, 2020-2027

Market Estimates & Forecast, by Country, 2020-2027

8.3. Online Pharmacies

Market Estimates & Forecast, by Region, 2020-2027

Market Estimates & Forecast, by Country, 2020-2027

9. GLOBAL PAIN RELIEF MEDICATION MARKET, BY REGION

9.1. Overview

9.2. Americas

9.2.1. North America

9.2.1.1. US

9.2.1.2. Canada

9.2.2. Latin America

9.3. Europe

9.3.1. Western Europe

9.3.1.1. Germany

9.3.1.2. France

9.3.1.3. Italy

9.3.1.4. Spain

9.3.1.5. UK

9.3.1.6. Rest of Western Europe

9.3.2. Eastern Europe

9.4. Asia-Pacific

9.4.1. Japan

9.4.2. China

9.4.3. India

9.4.4. Australia

9.4.5. South Korea

9.4.6. Rest of Asia-Pacific

9.5. Middle East & Africa

9.5.1. Middle East

9.5.2. Africa

10. COMPANY LANDSCAPE

10.1. Overview

10.2. Competitor Dashboard

10.3. Major Growth Strategy in the Global Pain Relief Medication Market

10.4. Competitive Benchmarking

10.5. The Leading Player in terms of Number of Developments in the Global Pain Relief Medication Market

10.6. Key Developments & Growth Strategies

10.7. Major Players Financial Matrix & Market Ratio

11. COMPANY PROFILES

11.1. AbbVie Inc.

11.1.1. Company Overview

11.1.2. Products/Services Offered

11.1.3. Financial Overview

11.1.4. Key Developments

11.1.5. SWOT Analysis

11.1.6. Key Strategies

11.2. Allergan PLC

11.3. Astellas Pharma Inc.

11.4. Bayer

11.5. AbbVie Inc. Idec

11.6. Boehringer Ingelheim International GmbH

11.7. Bristol-Myers Squibb

11.8. Eli Lilly and Company

11.9. GlaxoSmithKline

11.10. Mallinckrodt Pharmaceuticals

11.11. Pfizer, Inc.

11.12. Purdue Pharma

11.13. Sanofi

11.14. Teva Pharmaceutical Industries Ltd

11.15. Others

12. APPENDIX

12.1. References

12.2. Related Reports


LIST OF TABLES

TABLE 1 GLOBAL PAIN RELIEF MEDICATION MARKET SYNOPSIS, 2020-2027

TABLE 2 GLOBAL PAIN RELIEF MEDICATION MARKET ESTIMATES & FORECAST, 2020-2027 (USD MILLION)

TABLE 3 GLOBAL PAIN RELIEF MEDICATION MARKET, BY DRUG CLASS, 2020-2027 (USD MILLION)

TABLE 4 GLOBAL PAIN RELIEF MEDICATION MARKET, BY INDICATION, 2020-2027 (USD MILLION)

TABLE 5 GLOBAL PAIN RELIEF MEDICATION MARKET, BY DISTRIBUTION CHANNEL, 2020-2027 (USD MILLION)

TABLE 6 GLOBAL PAIN RELIEF MEDICATION MARKET, BY REGION, 2020-2027 (USD MILLION)

TABLE 7 NORTH AMERICA: PAIN RELIEF MEDICATION MARKET, BY DRUG CLASS, 2020-2027 (USD MILLION)

TABLE 8 NORTH AMERICA: PAIN RELIEF MEDICATION MARKET, BY INDICATION, 2020-2027 (USD MILLION)

TABLE 9 NORTH AMERICA: PAIN RELIEF MEDICATION MARKET, BY DISTRIBUTION CHANNEL, 2020-2027 (USD MILLION)

TABLE 10 US: PAIN RELIEF MEDICATION MARKET, BY DRUG CLASS, 2020-2027 (USD MILLION)

TABLE 11 US: PAIN RELIEF MEDICATION MARKET, BY INDICATION, 2020-2027 (USD MILLION)

TABLE 12 US: PAIN RELIEF MEDICATION MARKET, BY DISTRIBUTION CHANNEL, 2020-2027 (USD MILLION)

TABLE 13 CANADA: PAIN RELIEF MEDICATION MARKET, BY DRUG CLASS, 2020-2027 (USD MILLION)

TABLE 14 CANADA: PAIN RELIEF MEDICATION MARKET, BY INDICATION, 2020-2027 (USD MILLION)

TABLE 15 CANADA: PAIN RELIEF MEDICATION MARKET, BY DISTRIBUTION CHANNEL, 2020-2027 (USD MILLION)

TABLE 16 LATIN AMERICA: PAIN RELIEF MEDICATION MARKET, BY DRUG CLASS, 2020-2027 (USD MILLION)

TABLE 17 LATIN AMERICA: PAIN RELIEF MEDICATION MARKET, BY INDICATION, 2020-2027 (USD MILLION)

TABLE 18 LATIN AMERICA: PAIN RELIEF MEDICATION MARKET, BY DISTRIBUTION CHANNEL, 2020-2027 (USD MILLION)

TABLE 19 EUROPE: PAIN RELIEF MEDICATION MARKET, BY DRUG CLASS, 2020-2027 (USD MILLION)

TABLE 20 EUROPE: PAIN RELIEF MEDICATION MARKET, BY INDICATION, 2020-2027 (USD MILLION)

TABLE 21 EUROPE: PAIN RELIEF MEDICATION MARKET, BY DISTRIBUTION CHANNEL, 2020-2027 (USD MILLION)

TABLE 22 WESTERN EUROPE: PAIN RELIEF MEDICATION MARKET, BY DRUG CLASS, 2020-2027 (USD MILLION)

TABLE 23 WESTERN EUROPE: PAIN RELIEF MEDICATION MARKET, BY INDICATION, 2020-2027 (USD MILLION)

TABLE 24 WESTERN EUROPE: PAIN RELIEF MEDICATION MARKET, BY DISTRIBUTION CHANNEL, 2020-2027 (USD MILLION)

TABLE 25 EASTERN EUROPE: PAIN RELIEF MEDICATION MARKET, BY DRUG CLASS, 2020-2027 (USD MILLION)

TABLE 26 EASTERN EUROPE: PAIN RELIEF MEDICATION MARKET, BY INDICATION, 2020-2027 (USD MILLION)

TABLE 27 EASTERN EUROPE: PAIN RELIEF MEDICATION MARKET, BY DISTRIBUTION CHANNEL, 2020-2027 (USD MILLION)

TABLE 28 ASIA-PACIFIC: PAIN RELIEF MEDICATION MARKET, BY DRUG CLASS, 2020-2027 (USD MILLION)

TABLE 29 ASIA-PACIFIC: PAIN RELIEF MEDICATION MARKET, BY INDICATION, 2020-2027 (USD MILLION)

TABLE 30 ASIA-PACIFIC: PAIN RELIEF MEDICATION MARKET, BY DISTRIBUTION CHANNEL, 2020-2027 (USD MILLION)

TABLE 31 MIDDLE EAST & AFRICA: PAIN RELIEF MEDICATION MARKET, BY DRUG CLASS, 2020-2027 (USD MILLION)

TABLE 32 MIDDLE EAST & AFRICA: PAIN RELIEF MEDICATION MARKET, BY INDICATION, 2020-2027 (USD MILLION)

TABLE 33 MIDDLE EAST & AFRICA: PAIN RELIEF MEDICATION MARKET, BY DISTRIBUTION CHANNEL, 2020-2027 (USD MILLION)


LIST OF FIGURES

FIGURE 1 RESEARCH PROCESS

FIGURE 2 MARKET STRUCTURE FOR THE GLOBAL PAIN RELIEF MEDICATION MARKET

FIGURE 3 MARKET DYNAMICS FOR THE GLOBAL PAIN RELIEF MEDICATION MARKET

FIGURE 4 GLOBAL PAIN RELIEF MEDICATION MARKET SHARE, BY DRUG CLASS, 2020 (%)

FIGURE 5 GLOBAL PAIN RELIEF MEDICATION MARKET SHARE, BY INDICATION, 2020 (%)

FIGURE 6 GLOBAL PAIN RELIEF MEDICATION MARKET SHARE, BY DISTRIBUTION CHANNEL, 2020 (%)

FIGURE 7 GLOBAL PAIN RELIEF MEDICATION MARKET SHARE, BY REGION, 2020 (%)

FIGURE 8 AMERICAS: PAIN RELIEF MEDICATION MARKET SHARE BY REGION, 2020 (%)

FIGURE 9 NORTH AMERICA: PAIN RELIEF MEDICATION MARKET SHARE, BY COUNTRY, 2020 (%)

FIGURE 10 EUROPE: PAIN RELIEF MEDICATION MARKET SHARE, BY REGION, 2020 (%)

FIGURE 11 WESTERN EUROPE: PAIN RELIEF MEDICATION MARKET SHARE, BY COUNTRY, 2020 (%)

FIGURE 12 ASIA-PACIFIC: PAIN RELIEF MEDICATION MARKET SHARE, BY COUNTRY, 2020 (%)

FIGURE 13 MIDDLE EAST & AFRICA: PAIN RELIEF MEDICATION MARKET SHARE, BY COUNTRY, 2020 (%)

FIGURE 14 GLOBAL PAIN RELIEF MEDICATION MARKET: COMPANY SHARE ANALYSIS, 2020 (%)

FIGURE 15 ABBVIE INC.: KEY FINANCIALS

FIGURE 16 ABBVIE INC.: SEGMENTAL REVENUE

FIGURE 17 ABBVIE INC.: REGIONAL REVENUE

FIGURE 18 ALLERGAN PLC: KEY FINANCIALS

FIGURE 19 ALLERGAN PLC: SEGMENTAL REVENUE

FIGURE 20 ALLERGAN PLC: REGIONAL REVENUE

FIGURE 21 ASTELLAS PHARMA INC.: KEY FINANCIALS

FIGURE 22 ASTELLAS PHARMA INC.: SEGMENTAL REVENUE

FIGURE 23 ASTELLAS PHARMA INC.: REGIONAL REVENUE

FIGURE 24 BAYER: KEY FINANCIALS

FIGURE 25 BAYER: SEGMENTAL REVENUE

FIGURE 26 BAYER: REGIONAL REVENUE

FIGURE 27 BIOGEN IDEC: KEY FINANCIALS

FIGURE 28 BIOGEN IDEC: SEGMENTAL REVENUE

FIGURE 29 BIOGEN IDEC: REGIONAL REVENUE

FIGURE 30 BOEHRINGER INGELHEIM INTERNATIONAL GMBH: KEY FINANCIALS

FIGURE 31 BOEHRINGER INGELHEIM INTERNATIONAL GMBH: SEGMENTAL REVENUE

FIGURE 32 BOEHRINGER INGELHEIM INTERNATIONAL GMBH: REGIONAL REVENUE

FIGURE 33 BRISTOL-MYERS SQUIBB: KEY FINANCIALS

FIGURE 34 BRISTOL-MYERS SQUIBB: SEGMENTAL REVENUE

FIGURE 35 BRISTOL-MYERS SQUIBB: REGIONAL REVENUE

FIGURE 36 ELI LILLY AND COMPANY: KEY FINANCIALS

FIGURE 37 ELI LILLY AND COMPANY: SEGMENTAL REVENUE

FIGURE 38 ELI LILLY AND COMPANY: REGIONAL REVENUE

FIGURE 39 GLAXOSMITHKLINE: KEY FINANCIALS

FIGURE 40 GLAXOSMITHKLINE: SEGMENTAL REVENUE

FIGURE 41 GLAXOSMITHKLINE: REGIONAL REVENUE

FIGURE 42 MALLINCKRODT PHARMACEUTICALS: KEY FINANCIALS

FIGURE 43 MALLINCKRODT PHARMACEUTICALS: SEGMENTAL REVENUE

FIGURE 44 MALLINCKRODT PHARMACEUTICALS: REGIONAL REVENUE

FIGURE 45 PFIZER, INC.: KEY FINANCIALS

FIGURE 46 PFIZER, INC.: SEGMENTAL REVENUE

FIGURE 47 PFIZER, INC.: REGIONAL REVENUE

FIGURE 48 PURDUE PHARMA: KEY FINANCIALS

FIGURE 49 PURDUE PHARMA: SEGMENTAL REVENUE

FIGURE 50 PURDUE PHARMA: REGIONAL REVENUE

FIGURE 51 SANOFI: KEY FINANCIALS

FIGURE 52 SANOFI: SEGMENTAL REVENUE

FIGURE 53 SANOFI: REGIONAL REVENUE

FIGURE 54 TEVA PHARMACEUTICAL INDUSTRIES LTD: KEY FINANCIALS

FIGURE 55 TEVA PHARMACEUTICAL INDUSTRIES LTD: SEGMENTAL REVENUE

FIGURE 56 TEVA PHARMACEUTICAL INDUSTRIES LTD: REGIONAL REVENUE



This table of content is tentative and subject to change as the research progresses.

Please Note:  Financial details of company cannot be provided if the information of the company is not available in public domain and or reliable source.

Pain Relief Medication Market